ABSTRACT

Objective: Pneumococcal diseases including invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) impose a substantial public health burden. This study performed a budget impact analysis of the use of pneumococcal conjugate vaccines (PCVs) in the National Immunization Program (NIP) in Colombia.

Methods: We compared the direct medical cost of the scenario without and with PCV vaccination using either pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) or 13-valent pneumococcal conjugate vaccine (PCV-13) over 5 years (2020–2024) from the health-care system perspective. Vaccine efficacy estimates were obtained from published sources and vaccine prices were taken from the Pan-American Health Organization Revolving Fund. Vaccine coverage was assumed to be 90% based on Colombia data.

Results: Using PHiD-CV in the NIP in Colombia would reduce the estimated cost for treating pneumococcal disease by US$46.1 m over the 2020–2024 period (US$40.2 m using PCV-13), with a budget impact of US$100.1 m for PHiD-CV (US$121.4 m for PCV-13), and would cost US$3.1 m less per year on vaccine doses than using PCV-13.

Conclusion: These findings are potentially valuable for the selection of vaccines for their national immunization programs under conditions of budgetary constraint.

摘要

目的：包括侵袭性肺炎球菌病 (IPD)、肺炎和急性中耳炎 (AOM) 在内的肺炎球菌疾病造成了巨大的公共卫生负担。本研究对哥伦比亚国家免疫计划 (NIP) 中肺炎球菌结合疫苗 (PCV) 的使用进行了预算影响分析。

方法：我们在 5 年内（2020 年）比较了使用肺炎球菌非可分型流感嗜血杆菌蛋白 D 结合疫苗 (PHiD-CV) 或 13 价肺炎球菌结合疫苗 (PCV-13) 接种 PCV 疫苗和未接种 PCV 疫苗的直接医疗费用–2024）从卫生保健系统的角度来看。疫苗功效估计来自公开的来源，疫苗价格来自泛美卫生组织循环基金。根据哥伦比亚的数据，疫苗覆盖率假设为 90%。

结果：在哥伦比亚的 NIP 中使用 PHiD-CV 将在 2020-2024 年期间将治疗肺炎球菌疾病的估计成本降低 4610 万美元（使用 PCV-13 为 4020 万美元），对 PHiD 的预算影响为 1.001 亿美元-CV（PCV-13 为 1.214 亿美元），与使用 PCV-13 相比，每年接种疫苗的费用将减少 310 万美元。

结论：这些发现对于在预算限制条件下为其国家免疫计划选择疫苗具有潜在价值。